Hi-Tech Pharmacal Inc (HITK.O)
20.46USD
9 Feb 2010
$0.28 (+1.39%)
$20.46
--
$20.80
$20.07
186,196
302,133
$29.89
$4.50
HITK.O
About
Overall
| Beta: | 1.54 |
| Market Cap (Mil.): | $247.20 |
| Shares Outstanding (Mil.): | 12.08 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| HITK.O | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 10.40 | 1.96 | 3.76 |
| EPS (TTM): | 1,763.11 | -- | -- |
| ROI: | 23.99 | 0.92 | 2.30 |
| ROE: | 24.19 | 1.27 | 2.82 |
UPDATE 1-Hi-Tech Q2 profit soars, shares rise
Dec 9 (Reuters) - Hi-Tech Pharmacal Co Inc posted nearly a six-fold jump in quarterly profit as it sold more higher-margin products like generic eye drops, sending its shares up 11 percent in pre-market trade.
HEADLINE STOCKS-Some U.S. stocks on the move on Sept. 9
(Updates to afternoon trading; adds DuPont, Barrick, K12, Ista, UPS, Starbucks, Fortress, Juniper, Genworth, Palm, Cepheid, eBay, MSC Software)
HEADLINE STOCKS-Some U.S. stocks on the move on Sept. 9
(Updates to after the open, adds Textron, Korn/Ferry, United Natural, Fifth Third, Hi-Tech Pharmacal, E*Trade)
BEFORE THE BELL-Hi-Tech Pharmacal shares up after Q1 results
NEW YORK, Sept 9 (Reuters) - Shares of Hi-Tech Pharmacal rose 17 percent to $20.14 in premarket trading on Wednesday after the company reported first-quarter results.
UPDATE 1-Hi-Tech Pharmacal Q1 profit soars, shares jump
Sept 9 (Reuters) - Hi-Tech Pharmacal Co Inc posted an almost six-fold jump in quarterly profit, boosted by strong generic sales, sending its shares up 19 percent in pre-market trade.
UPDATE 1-Hi-Tech Pharmacal posts better Q4 profit, shares jump
July 14 (Reuters) - Hi-Tech Pharmacal Inc posted higher quarterly profit, helped by generic sales that almost doubled, sending its shares up as much as 31 percent.
UPDATE 1-Hi-Tech Pharmacal posts Q2 profit, shares jump
Dec 9 (Reuters) - Hi-Tech Pharmacal Co Inc swung to a quarterly profit, boosted by new product launches and a 44 percent jump in generic pharmaceutical product sales, sending its shares up as much as 35 percent.
UPDATE 1-Hi-Tech Pharmacal posts Q3 loss
March 10 (Reuters) - Hi-Tech Pharmacal Co Inc posted a third-quarter loss hurt by lower sales due to a milder-than-expected cough and cold season, sending shares down as much as 11 percent.
Hi-Tech Pharmacal gets FDA nod for generic cough drug
Feb 11 (Reuters) - Hi-Tech Pharmacal Co Inc said it received approval from the U.S. Food and Drug Administration for its generic version of Endo Pharmaceuticals Holdings Inc's cough drug, Hycodan.
Hi-Tech Pharmacal gets final FDA nod for generic Flonase
Jan 16 (Reuters) - Hi-Tech Pharmacal Co Inc said U.S. regulators granted final approval for its fluticasone propionate nasal spray, an AB-rated generic version of GlaxoSmithKline's Flonase, for the treatment of seasonal and perennial, allergic and non-allergic rhinitis.
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
